Vaccine Must Have At Least 50% Efficacy In Phase 3 Trials: Drug Authority

September 23, 2020 at 02:11PMThe Drugs Controller General of India (DCGI) has issued a new set of guidelines, focusing on safety, immunogenicity and efficacy parameters for pharma giants who are developing COVID-19 vaccines.

from NDTV News - Topstories https://ift.tt/2EntxSq
https://ift.tt/eA8V8J via